RPRX - Royalty Pharma plc - Ordinary Shares - Class A
IEX Last Trade
29.03
-0.100 -0.344%
Share volume: 2,939,681
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$29.13
-0.10
-0.34%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-08 | 2023-02-15 | 2023-05-09 | 2023-08-08 | 2023-11-08 | 2024-02-15 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 17.740 B | 17.673 B | 16.813 B | 17.074 B | 17.121 B | 15.856 B | 16.382 B | 16.131 B | |
| Current Assets | 3.504 B | 2.342 B | 2.555 B | 2.631 B | 2.954 B | 1.729 B | 1.274 B | 1.560 B | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 706.363 M | 766.372 M | 781.839 M | 614.592 M | 740.134 M | 748.944 M | 742.236 M | 665.492 M | |
| Short Term Investments | 706.363 M | 766.372 M | 781.839 M | 614.592 M | 740.134 M | 748.944 M | 742.236 M | 665.492 M | |
| Total Receivables | 35.347 M | 34.843 M | 36.597 M | 38.440 M | 35.228 M | 37.913 M | 36.647 M | 22.227 M | |
| Current Cash | 2.762 B | 1.541 B | 1.736 B | 1.978 B | 2.178 B | 941.748 M | 495.310 M | 872.000 M | |
| Total Non-current Assets | 14.237 B | 15.330 B | 14.259 B | 14.443 B | 14.168 B | 14.127 B | 15.108 B | 14.571 B | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 13.457 B | 14.318 B | 13.523 B | 13.690 B | 13.297 B | 13.251 B | 14.095 B | 13.470 B | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 17.740 B | 17.673 B | 16.813 B | 17.074 B | 17.121 B | 15.856 B | 16.382 B | 16.131 B | |
| Total liabilities | 11.713 B | 11.521 B | 11.185 B | 11.120 B | 10.840 B | 9.717 B | 9.855 B | 9.631 B | |
| Total current liabilities | 182.327 M | 1.132 B | 1.167 B | 1.117 B | 1.172 B | 127.933 M | 161.377 M | 124.574 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 43.700 M | 9.900 M | 2.500 M | 12.300 M | 8.500 M | 11.300 M | 900.000 K | 3.220 M | |
| Current long term debt | 0.000 | 996.583 M | 997.512 M | 998.441 M | 999.370 M | 0.000 | 0.000 | 0.000 | |
| Long term debt | 7.106 B | 6.115 B | 6.119 B | 6.123 B | 6.127 B | 6.131 B | 6.135 B | 6.139 B | |
| Other liabilities | 43.700 M | 9.900 M | 2.500 M | 12.300 M | 8.500 M | 11.300 M | 900.000 K | 3.220 M | |
| Minority interest | 4.381 B | 4.264 B | 3.897 B | 3.868 B | 3.532 B | 3.446 B | 3.558 B | 3.364 B | |
| Total Shareholder equity | 6.027 B | 6.152 B | 5.628 B | 5.954 B | 6.282 B | 6.139 B | 6.526 B | 6.500 B | |
| Common stock | 436.318 M | 439.293 M | 442.285 M | 445.612 M | 450.405 M | 448.439 M | 445.948 M | 448.623 M | |
| Retained earnings | 2.446 B | 2.505 B | 1.965 B | 2.217 B | 2.253 B | 2.135 B | 2.518 B | 2.427 B |